| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
135,363,000 |
| Market
Cap: |
860.91(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.9 - $13.14 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Relay Therapeutics is a clinical-stage precision medicines company. Co.'s operating focus is on enhancing small molecule therapeutic discovery in targeted oncology. Co. is advancing a pipeline of medicines to address targets in precision oncology, including its primary product candidates, RLY-1971 and RLY-4008, as well as its PI3Ka mutant selective program (RLY-PI3K1047 program). Co.'s Dynamo platform integrates an array of experimental and computational approaches and may also be applied to other areas of precision medicine, such as genetic disease. In addition to the three product candidates, Co also has five discovery stage programs across precision oncology and genetic disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
9,108 |
19,680 |
38,129 |
475,737 |
| Total Sell Value |
$60,433 |
$165,730 |
$331,907 |
$10,207,536 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
8 |
16 |
32 |
93 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Catinazzo Thomas |
Chief Financial Officer |
• – – |
2022-03-29 |
4 |
S |
$29.87 |
$8,423 |
D/D |
(282) |
53,977 |
|
39% |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-24 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
94,926 |
|
-37% |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-24 |
4 |
OE |
$4.12 |
$41,200 |
D/D |
10,000 |
104,926 |
|
- |
|
| Catinazzo Thomas |
Chief Financial Officer |
• – – |
2022-03-24 |
4 |
AS |
$30.00 |
$398,580 |
D/D |
(13,286) |
54,259 |
|
-37% |
|
| Catinazzo Thomas |
Chief Financial Officer |
• – – |
2022-03-24 |
4 |
OE |
$4.12 |
$54,738 |
D/D |
13,286 |
67,545 |
|
- |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-10 |
4 |
AS |
$25.00 |
$250,000 |
D/D |
(10,000) |
94,926 |
|
-9% |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-10 |
4 |
OE |
$4.12 |
$41,200 |
D/D |
10,000 |
104,926 |
|
- |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-01 |
4 |
AS |
$23.88 |
$191,040 |
D/D |
(8,000) |
94,926 |
|
-19% |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-03-01 |
4 |
OE |
$4.12 |
$32,960 |
D/D |
8,000 |
102,926 |
|
- |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-02-22 |
4 |
AS |
$20.94 |
$481,577 |
D/D |
(22,994) |
94,926 |
|
-14% |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-02-22 |
4 |
OE |
$4.12 |
$32,960 |
D/D |
8,000 |
117,920 |
|
- |
|
| Catinazzo Thomas |
Chief Financial Officer |
• – – |
2022-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
39,270 |
54,259 |
|
- |
|
| Bergstrom Donald A |
President, R&D |
• – – |
2022-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
64,950 |
109,920 |
|
- |
|
| Porter Andy |
Chief Administrative Officer |
• – – |
2022-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
24,170 |
47,317 |
|
- |
|
| Adams Brian |
Chief Legal Officer |
• – – |
2022-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
39,270 |
64,917 |
|
- |
|
| Patel Sanjiv |
President and CEO |
• • – |
2021-12-31 |
4 |
A |
$26.10 |
$17,174 |
D/D |
658 |
253,740 |
|
- |
|
| Adams Brian |
General Counsel |
• – – |
2021-12-31 |
4 |
A |
$26.10 |
$17,174 |
D/D |
658 |
25,647 |
|
- |
|
| Bergstrom Donald A |
See Remarks |
• – – |
2021-12-27 |
4 |
S |
$33.10 |
$21,482 |
D/D |
(649) |
44,970 |
|
28% |
|
| Catinazzo Thomas |
Senior Vice President, Finance |
• – – |
2021-12-27 |
4 |
S |
$33.10 |
$9,765 |
D/D |
(295) |
14,989 |
|
28% |
|
| Porter Andy |
See Remarks |
• – – |
2021-12-27 |
4 |
S |
$33.10 |
$8,606 |
D/D |
(260) |
23,147 |
|
28% |
|
| Adams Brian |
General Counsel |
• – – |
2021-12-27 |
4 |
S |
$33.10 |
$9,765 |
D/D |
(295) |
24,989 |
|
28% |
|
| Porter Andy |
See RemarksOfficer |
• – – |
2021-12-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,407 |
|
-18% |
|
| Adams Brian |
General Counsel |
• – – |
2021-11-15 |
4 |
AS |
$35.42 |
$230,230 |
D/D |
(6,500) |
25,284 |
|
-9% |
|
| Adams Brian |
General Counsel |
• – – |
2021-11-15 |
4 |
OE |
$4.12 |
$26,780 |
D/D |
6,500 |
31,784 |
|
- |
|
| Bergstrom Donald A |
See Remarks |
• – – |
2021-10-15 |
4 |
AS |
$34.15 |
$1,024,500 |
D/D |
(30,000) |
45,619 |
|
-29% |
|
229 Records found
|
|
Page 7 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (0.93%) 
